SARS-COV-2 VACCINE

PreclinicalVaccine

Moderna

SARS-COV-2 VACCINE is one of 135 biologic programs targeting Kidney Transplant. It is currently in Preclinical.

Indications

Total Trials

Active Trials

134

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney TransplantActive, not recruiting

Liver DiseaseActive, not recruiting

COVID-19Active, not recruiting

Kidney FailureActive, not recruiting

Kidney TransplantPreclinical

Active, not recruiting

Liver DiseasePreclinical

Active, not recruiting

COVID-19Preclinical

Active, not recruiting

Kidney FailurePreclinical

Active, not recruiting

Competition

Competitive Landscape

317 competitors in COVID-19

#DrugCompanyPhaseTrials

Statins

Sanofi

Preclinical

1 2

Glucocorticoid

AbbVie

Preclinical

1 3

Rayaldee

OOrganon and Co

Preclinical

1 4

Blood Taken

HHospices Civils de Lyon

Preclinical

1 5

SARS-COV-2 VACCINE

Moderna

Preclinical

2 6

Sivelestat Sodium

TThe First Hospital of Jilin University

Preclinical

1 7

Disease-Modifying Anti-Rheumatic Drugs

Roche

Preclinical

1 8

Pfizer-COVID-19 Vaccine

Moderna

Preclinical

1 9

Olokizumab

UCB

Preclinical

1 10

Covid Infection

KKing's College London

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Active, not recruiting

Vaccine Response

NCT06605625

Clinical

Trials by Indication[1]

Severe Acute Respiratory Syndrome2 trials

Study of a Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Adjuvanted Inactivated Vaccine in Healthy Adults

Terminated·OOsman ERGANIS, PhD, Prof·Phase 1·NCT04866069·50 enrolled

Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Immune Kidney Transplant Study (COVID-19)

Active, not recruiting·OOslo University Hospital··NCT04747522·150 enrolled

COVID-192 trials

Safety and Immune Response of COVID-19 Vaccination in Patients With Basic Disease

Unknown status·TThe Second Affiliated Hospital of Chongqing Medical University··NCT05043246·2,300 enrolled

COVID-19 Vaccines Associated Malaise

Completed·UUniversity Hospital, Caen··NCT05234333·1,534,706 enrolled

Unknown status·UUniversity of Ioannina··NCT04932876·100 enrolled

4 more indications

Vaccine Response1 trial

Vaccine Responses in Cancer

Active, not recruiting·—··NCT06605625·250 enrolled

Liver Disease1 trial

Safety and Immune Response of COVID-19 Vaccination in Patients With Chronic Liver Diseases

Unknown status·TThe Second Affiliated Hospital of Chongqing Medical University··NCT05007665·2,000 enrolled

Influenza1 trial

Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age

Completed· Moderna logo

Moderna·Phase 3·NCT06694389·2,457 enrolled

Kidney Failure1 trial

IMPACT OF KIDNEY FAILURE ON THE REGULATION OF HUMORAL RESPONSE TO VACCINATION

Not yet recruiting·FFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico··NCT06635525·146 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for SARS-COV-2 VACCINE. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SARS-COV-2 VACCINE compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SARS-COV-2 VACCINE. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Moderna company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Preclinical[1]
Company: Moderna

SARS-COV-2 VACCINE

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Severe Acute Respiratory Syndrome2 trials

COVID-192 trials

Overweight1 trial

SARS-CoV-21 trial

Kidney Transplant1 trial

Vaccine Response1 trial

Liver Disease1 trial

Influenza1 trial

Kidney Failure1 trial

References

Drug Info

Quick Facts

Related News